Cargando…
Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
This image illustrates a multimodal therapeutic strategy for an iodine-refractory BRAF-mutated metastatic papillary thyroid carcinoma with reversed radioiodine resistance using BRAF inhibitors.
Autores principales: | Huillard, Olivier, Tenenbaum, Florence, Clerc, Jerome, Goldwasser, Francois, Groussin, Lionel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686703/ https://www.ncbi.nlm.nih.gov/pubmed/29264486 http://dx.doi.org/10.1210/js.2016-1114 |
Ejemplares similares
-
MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data
por: Schubert, Louis, et al.
Publicado: (2023) -
The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020) -
Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021) -
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF(V600E) Mutation
por: Anekpuritanang, Tauangtham, et al.
Publicado: (2021) -
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
por: Zhang, Honglai, et al.
Publicado: (2018)